Compugen Ltd. (CGEN) Stock Competitors & Peer Comparison
See (CGEN) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CGEN | $2.02 | -0.98% | 191M | 5.32 | $0.38 | N/A |
| NVO | $43.92 | +0.09% | 195.1B | 10.38 | $4.23 | +4.11% |
| VRTX | $450.46 | +1.24% | 114.4B | 26.73 | $16.86 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $614.98 | +0.46% | 63.3B | 15.01 | $40.95 | +0.59% |
| ARGX | $884.20 | -1.04% | 54.7B | 39.28 | $22.51 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $287.80 | +1.75% | 38.4B | 72.13 | $3.99 | N/A |
| RVMDW | $6.36 | +7.07% | 35.5B | N/A | N/A | N/A |
| RVMD | $160.06 | +4.02% | 34B | -22.51 | -$7.11 | N/A |
Stock Comparison
CGEN vs NVO Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, NVO has a market cap of 195.1B. Regarding current trading prices, CGEN is priced at $2.02, while NVO trades at $43.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas NVO's P/E ratio is 10.38. In terms of profitability, CGEN's ROE is +0.48%, compared to NVO's ROE of +0.66%. Regarding short-term risk, CGEN is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check NVO's competition here
CGEN vs VRTX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, VRTX has a market cap of 114.4B. Regarding current trading prices, CGEN is priced at $2.02, while VRTX trades at $450.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas VRTX's P/E ratio is 26.73. In terms of profitability, CGEN's ROE is +0.48%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, CGEN is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check VRTX's competition here
CGEN vs VRNA Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CGEN is priced at $2.02, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CGEN's ROE is +0.48%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, CGEN is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check VRNA's competition here
CGEN vs REGN Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, REGN has a market cap of 63.3B. Regarding current trading prices, CGEN is priced at $2.02, while REGN trades at $614.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas REGN's P/E ratio is 15.01. In terms of profitability, CGEN's ROE is +0.48%, compared to REGN's ROE of +0.14%. Regarding short-term risk, CGEN is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check REGN's competition here
CGEN vs ARGX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, ARGX has a market cap of 54.7B. Regarding current trading prices, CGEN is priced at $2.02, while ARGX trades at $884.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas ARGX's P/E ratio is 39.28. In terms of profitability, CGEN's ROE is +0.48%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, CGEN is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check ARGX's competition here
CGEN vs SGEN Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CGEN is priced at $2.02, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CGEN's ROE is +0.48%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CGEN is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check SGEN's competition here
CGEN vs ALNY Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, ALNY has a market cap of 38.4B. Regarding current trading prices, CGEN is priced at $2.02, while ALNY trades at $287.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas ALNY's P/E ratio is 72.13. In terms of profitability, CGEN's ROE is +0.48%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, CGEN is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check ALNY's competition here
CGEN vs RVMDW Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, RVMDW has a market cap of 35.5B. Regarding current trading prices, CGEN is priced at $2.02, while RVMDW trades at $6.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas RVMDW's P/E ratio is N/A. In terms of profitability, CGEN's ROE is +0.48%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, CGEN is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check RVMDW's competition here
CGEN vs RVMD Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, RVMD has a market cap of 34B. Regarding current trading prices, CGEN is priced at $2.02, while RVMD trades at $160.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas RVMD's P/E ratio is -22.51. In terms of profitability, CGEN's ROE is +0.48%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, CGEN is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check RVMD's competition here
CGEN vs RPRX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, RPRX has a market cap of 23.3B. Regarding current trading prices, CGEN is priced at $2.02, while RPRX trades at $54.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas RPRX's P/E ratio is 28.56. In terms of profitability, CGEN's ROE is +0.48%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, CGEN is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check RPRX's competition here
CGEN vs UTHR Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, UTHR has a market cap of 23.3B. Regarding current trading prices, CGEN is priced at $2.02, while UTHR trades at $549.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas UTHR's P/E ratio is 20.34. In terms of profitability, CGEN's ROE is +0.48%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CGEN is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check UTHR's competition here
CGEN vs BNTX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, BNTX has a market cap of 23B. Regarding current trading prices, CGEN is priced at $2.02, while BNTX trades at $90.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas BNTX's P/E ratio is -15.52. In terms of profitability, CGEN's ROE is +0.48%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, CGEN is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check BNTX's competition here
CGEN vs ROIV Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, ROIV has a market cap of 21.6B. Regarding current trading prices, CGEN is priced at $2.02, while ROIV trades at $30.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas ROIV's P/E ratio is -55.61. In terms of profitability, CGEN's ROE is +0.48%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, CGEN is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check ROIV's competition here
CGEN vs INSM Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, INSM has a market cap of 21.1B. Regarding current trading prices, CGEN is priced at $2.02, while INSM trades at $97.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas INSM's P/E ratio is -16.92. In terms of profitability, CGEN's ROE is +0.48%, compared to INSM's ROE of -1.30%. Regarding short-term risk, CGEN is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check INSM's competition here
CGEN vs MRNA Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, MRNA has a market cap of 20.7B. Regarding current trading prices, CGEN is priced at $2.02, while MRNA trades at $52.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas MRNA's P/E ratio is -6.40. In terms of profitability, CGEN's ROE is +0.48%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, CGEN is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check MRNA's competition here
CGEN vs INCY Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, INCY has a market cap of 20.4B. Regarding current trading prices, CGEN is priced at $2.02, while INCY trades at $101.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas INCY's P/E ratio is 14.40. In terms of profitability, CGEN's ROE is +0.48%, compared to INCY's ROE of +0.29%. Regarding short-term risk, CGEN is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check INCY's competition here
CGEN vs BGNE Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CGEN is priced at $2.02, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CGEN's ROE is +0.48%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, CGEN is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check BGNE's competition here
CGEN vs DNA-WT Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CGEN is priced at $2.02, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CGEN's ROE is +0.48%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, CGEN is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check DNA-WT's competition here
CGEN vs NBIX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, NBIX has a market cap of 16B. Regarding current trading prices, CGEN is priced at $2.02, while NBIX trades at $159.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas NBIX's P/E ratio is 24.58. In terms of profitability, CGEN's ROE is +0.48%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, CGEN is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check NBIX's competition here
CGEN vs GMAB Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, GMAB has a market cap of 15.1B. Regarding current trading prices, CGEN is priced at $2.02, while GMAB trades at $24.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas GMAB's P/E ratio is 18.76. In terms of profitability, CGEN's ROE is +0.48%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, CGEN is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check GMAB's competition here
CGEN vs JAZZ Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, JAZZ has a market cap of 14.5B. Regarding current trading prices, CGEN is priced at $2.02, while JAZZ trades at $230.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas JAZZ's P/E ratio is 1921.58. In terms of profitability, CGEN's ROE is +0.48%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, CGEN is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check JAZZ's competition here
CGEN vs ASND Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, ASND has a market cap of 13.9B. Regarding current trading prices, CGEN is priced at $2.02, while ASND trades at $223.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas ASND's P/E ratio is 25.58. In terms of profitability, CGEN's ROE is +0.48%, compared to ASND's ROE of -56.42%. Regarding short-term risk, CGEN is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check ASND's competition here
CGEN vs EXEL Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, CGEN is priced at $2.02, while EXEL trades at $53.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas EXEL's P/E ratio is 17.55. In terms of profitability, CGEN's ROE is +0.48%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, CGEN is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check EXEL's competition here
CGEN vs BBIO Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, BBIO has a market cap of 13.3B. Regarding current trading prices, CGEN is priced at $2.02, while BBIO trades at $68.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas BBIO's P/E ratio is -18.18. In terms of profitability, CGEN's ROE is +0.48%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, CGEN is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check BBIO's competition here
CGEN vs AXSM Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, AXSM has a market cap of 13B. Regarding current trading prices, CGEN is priced at $2.02, while AXSM trades at $253.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas AXSM's P/E ratio is -67.94. In terms of profitability, CGEN's ROE is +0.48%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, CGEN is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check AXSM's competition here
CGEN vs KRTX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CGEN is priced at $2.02, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CGEN's ROE is +0.48%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CGEN is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check KRTX's competition here
CGEN vs IONS Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, IONS has a market cap of 12.2B. Regarding current trading prices, CGEN is priced at $2.02, while IONS trades at $73.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas IONS's P/E ratio is -36.80. In terms of profitability, CGEN's ROE is +0.48%, compared to IONS's ROE of -0.59%. Regarding short-term risk, CGEN is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check IONS's competition here
CGEN vs MDGL Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, MDGL has a market cap of 11.5B. Regarding current trading prices, CGEN is priced at $2.02, while MDGL trades at $499.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas MDGL's P/E ratio is -36.99. In terms of profitability, CGEN's ROE is +0.48%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, CGEN is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check MDGL's competition here
CGEN vs RNAM Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CGEN is priced at $2.02, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CGEN's ROE is +0.48%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, CGEN is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check RNAM's competition here
CGEN vs SMMT Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, SMMT has a market cap of 11B. Regarding current trading prices, CGEN is priced at $2.02, while SMMT trades at $14.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas SMMT's P/E ratio is -8.89. In terms of profitability, CGEN's ROE is +0.48%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, CGEN is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check SMMT's competition here
CGEN vs ARWR Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, ARWR has a market cap of 10.9B. Regarding current trading prices, CGEN is priced at $2.02, while ARWR trades at $77.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas ARWR's P/E ratio is -33.99. In terms of profitability, CGEN's ROE is +0.48%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, CGEN is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check ARWR's competition here
CGEN vs BMRN Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, CGEN is priced at $2.02, while BMRN trades at $55.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas BMRN's P/E ratio is 40.04. In terms of profitability, CGEN's ROE is +0.48%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, CGEN is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check BMRN's competition here
CGEN vs KRYS Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, KRYS has a market cap of 9.6B. Regarding current trading prices, CGEN is priced at $2.02, while KRYS trades at $324.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas KRYS's P/E ratio is 43.47. In terms of profitability, CGEN's ROE is +0.48%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, CGEN is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check KRYS's competition here
CGEN vs RXDX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CGEN is priced at $2.02, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CGEN's ROE is +0.48%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CGEN is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check RXDX's competition here
CGEN vs NUVL Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, CGEN is priced at $2.02, while NUVL trades at $123.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas NUVL's P/E ratio is -20.36. In terms of profitability, CGEN's ROE is +0.48%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, CGEN is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check NUVL's competition here
CGEN vs CORT Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, CORT has a market cap of 8.9B. Regarding current trading prices, CGEN is priced at $2.02, while CORT trades at $83.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas CORT's P/E ratio is 237.49. In terms of profitability, CGEN's ROE is +0.48%, compared to CORT's ROE of +0.08%. Regarding short-term risk, CGEN is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check CORT's competition here
CGEN vs CYTK Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, CYTK has a market cap of 8.9B. Regarding current trading prices, CGEN is priced at $2.02, while CYTK trades at $71.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas CYTK's P/E ratio is -10.42. In terms of profitability, CGEN's ROE is +0.48%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, CGEN is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check CYTK's competition here
CGEN vs TECH Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, TECH has a market cap of 8.8B. Regarding current trading prices, CGEN is priced at $2.02, while TECH trades at $56.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas TECH's P/E ratio is 80.23. In terms of profitability, CGEN's ROE is +0.48%, compared to TECH's ROE of +0.05%. Regarding short-term risk, CGEN is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check TECH's competition here
CGEN vs IMGN Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CGEN is priced at $2.02, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CGEN's ROE is +0.48%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CGEN is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check IMGN's competition here
CGEN vs HALO Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, HALO has a market cap of 8.5B. Regarding current trading prices, CGEN is priced at $2.02, while HALO trades at $71.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas HALO's P/E ratio is 25.01. In terms of profitability, CGEN's ROE is +0.48%, compared to HALO's ROE of +1.26%. Regarding short-term risk, CGEN is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check HALO's competition here
CGEN vs BPMC Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CGEN is priced at $2.02, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CGEN's ROE is +0.48%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, CGEN is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check BPMC's competition here
CGEN vs CERE Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CGEN is priced at $2.02, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas CERE's P/E ratio is -16.47. In terms of profitability, CGEN's ROE is +0.48%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CGEN is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check CERE's competition here
CGEN vs TGTX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, TGTX has a market cap of 7.7B. Regarding current trading prices, CGEN is priced at $2.02, while TGTX trades at $50.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas TGTX's P/E ratio is 17.59. In terms of profitability, CGEN's ROE is +0.48%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, CGEN is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check TGTX's competition here
CGEN vs IBRX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, CGEN is priced at $2.02, while IBRX trades at $7.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas IBRX's P/E ratio is -8.39. In terms of profitability, CGEN's ROE is +0.48%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, CGEN is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check IBRX's competition here
CGEN vs MTSR Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CGEN is priced at $2.02, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CGEN's ROE is +0.48%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, CGEN is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check MTSR's competition here
CGEN vs ALKS Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, ALKS has a market cap of 7.4B. Regarding current trading prices, CGEN is priced at $2.02, while ALKS trades at $44.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas ALKS's P/E ratio is 49.29. In terms of profitability, CGEN's ROE is +0.48%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, CGEN is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check ALKS's competition here
CGEN vs PTGX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, PTGX has a market cap of 7.2B. Regarding current trading prices, CGEN is priced at $2.02, while PTGX trades at $112.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas PTGX's P/E ratio is -62.13. In terms of profitability, CGEN's ROE is +0.48%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, CGEN is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check PTGX's competition here
CGEN vs PCVX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, PCVX has a market cap of 7.2B. Regarding current trading prices, CGEN is priced at $2.02, while PCVX trades at $49.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas PCVX's P/E ratio is -7.19. In terms of profitability, CGEN's ROE is +0.48%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, CGEN is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check PCVX's competition here
CGEN vs KYMR Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, KYMR has a market cap of 7B. Regarding current trading prices, CGEN is priced at $2.02, while KYMR trades at $85.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas KYMR's P/E ratio is -23.91. In terms of profitability, CGEN's ROE is +0.48%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, CGEN is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check KYMR's competition here
CGEN vs IMVT Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, CGEN is priced at $2.02, while IMVT trades at $33.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas IMVT's P/E ratio is -12.07. In terms of profitability, CGEN's ROE is +0.48%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, CGEN is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check IMVT's competition here
CGEN vs MRUS Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CGEN is priced at $2.02, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CGEN's ROE is +0.48%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, CGEN is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check MRUS's competition here
CGEN vs ACLX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CGEN is priced at $2.02, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas ACLX's P/E ratio is -28.27. In terms of profitability, CGEN's ROE is +0.48%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, CGEN is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check ACLX's competition here
CGEN vs RETA Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CGEN is priced at $2.02, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas RETA's P/E ratio is -66.29. In terms of profitability, CGEN's ROE is +0.48%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CGEN is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check RETA's competition here
CGEN vs LEGN Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, LEGN has a market cap of 6.6B. Regarding current trading prices, CGEN is priced at $2.02, while LEGN trades at $35.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas LEGN's P/E ratio is -25.71. In terms of profitability, CGEN's ROE is +0.48%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, CGEN is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check LEGN's competition here
CGEN vs ABVX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, ABVX has a market cap of 6.4B. Regarding current trading prices, CGEN is priced at $2.02, while ABVX trades at $98.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas ABVX's P/E ratio is -18.47. In terms of profitability, CGEN's ROE is +0.48%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, CGEN is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check ABVX's competition here
CGEN vs LQDA Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, LQDA has a market cap of 6.4B. Regarding current trading prices, CGEN is priced at $2.02, while LQDA trades at $71.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas LQDA's P/E ratio is 422.35. In terms of profitability, CGEN's ROE is +0.48%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, CGEN is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check LQDA's competition here
CGEN vs PTCT Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, PTCT has a market cap of 6.4B. Regarding current trading prices, CGEN is priced at $2.02, while PTCT trades at $76.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas PTCT's P/E ratio is -30.22. In terms of profitability, CGEN's ROE is +0.48%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, CGEN is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check PTCT's competition here
CGEN vs RYTM Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, RYTM has a market cap of 6.2B. Regarding current trading prices, CGEN is priced at $2.02, while RYTM trades at $89.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas RYTM's P/E ratio is -28.66. In terms of profitability, CGEN's ROE is +0.48%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, CGEN is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check RYTM's competition here
CGEN vs CNTA Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, CGEN is priced at $2.02, while CNTA trades at $39.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas CNTA's P/E ratio is -22.34. In terms of profitability, CGEN's ROE is +0.48%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, CGEN is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check CNTA's competition here
CGEN vs BLTE Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, BLTE has a market cap of 5.8B. Regarding current trading prices, CGEN is priced at $2.02, while BLTE trades at $144.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas BLTE's P/E ratio is -56.79. In terms of profitability, CGEN's ROE is +0.48%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, CGEN is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check BLTE's competition here
CGEN vs COGT Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, CGEN is priced at $2.02, while COGT trades at $33.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas COGT's P/E ratio is -15.29. In terms of profitability, CGEN's ROE is +0.48%, compared to COGT's ROE of -0.83%. Regarding short-term risk, CGEN is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check COGT's competition here
CGEN vs CDTX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CGEN is priced at $2.02, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CGEN's ROE is +0.48%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, CGEN is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check CDTX's competition here
CGEN vs PRAX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, PRAX has a market cap of 5.6B. Regarding current trading prices, CGEN is priced at $2.02, while PRAX trades at $264.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas PRAX's P/E ratio is -19.77. In terms of profitability, CGEN's ROE is +0.48%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, CGEN is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check PRAX's competition here
CGEN vs ABCM Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CGEN is priced at $2.02, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CGEN's ROE is +0.48%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CGEN is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check ABCM's competition here
CGEN vs ISEE Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CGEN is priced at $2.02, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CGEN's ROE is +0.48%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CGEN is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check ISEE's competition here
CGEN vs SRRK Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, SRRK has a market cap of 5.5B. Regarding current trading prices, CGEN is priced at $2.02, while SRRK trades at $45.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas SRRK's P/E ratio is -13.31. In terms of profitability, CGEN's ROE is +0.48%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, CGEN is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check SRRK's competition here
CGEN vs APGE Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, APGE has a market cap of 5.3B. Regarding current trading prices, CGEN is priced at $2.02, while APGE trades at $86.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas APGE's P/E ratio is -19.91. In terms of profitability, CGEN's ROE is +0.48%, compared to APGE's ROE of -0.33%. Regarding short-term risk, CGEN is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check APGE's competition here
CGEN vs FBIOX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, CGEN is priced at $2.02, while FBIOX trades at $25.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas FBIOX's P/E ratio is N/A. In terms of profitability, CGEN's ROE is +0.48%, compared to FBIOX's ROE of N/A. Regarding short-term risk, CGEN is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check FBIOX's competition here
CGEN vs APLS Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, CGEN is priced at $2.02, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas APLS's P/E ratio is 38.35. In terms of profitability, CGEN's ROE is +0.48%, compared to APLS's ROE of +0.40%. Regarding short-term risk, CGEN is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check APLS's competition here
CGEN vs CGON Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, CGON has a market cap of 5.3B. Regarding current trading prices, CGEN is priced at $2.02, while CGON trades at $59.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas CGON's P/E ratio is -25.45. In terms of profitability, CGEN's ROE is +0.48%, compared to CGON's ROE of -0.23%. Regarding short-term risk, CGEN is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check CGON's competition here
CGEN vs CAI Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, CAI has a market cap of 5.1B. Regarding current trading prices, CGEN is priced at $2.02, while CAI trades at $18.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas CAI's P/E ratio is -6.59. In terms of profitability, CGEN's ROE is +0.48%, compared to CAI's ROE of +0.06%. Regarding short-term risk, CGEN is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check CAI's competition here
CGEN vs LGND Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, LGND has a market cap of 5.1B. Regarding current trading prices, CGEN is priced at $2.02, while LGND trades at $253.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas LGND's P/E ratio is 32.98. In terms of profitability, CGEN's ROE is +0.48%, compared to LGND's ROE of +0.16%. Regarding short-term risk, CGEN is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check LGND's competition here
CGEN vs CRSP Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, CGEN is priced at $2.02, while CRSP trades at $52.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas CRSP's P/E ratio is -8.53. In terms of profitability, CGEN's ROE is +0.48%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, CGEN is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check CRSP's competition here
CGEN vs MIRM Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, MIRM has a market cap of 5.1B. Regarding current trading prices, CGEN is priced at $2.02, while MIRM trades at $101.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas MIRM's P/E ratio is -7.43. In terms of profitability, CGEN's ROE is +0.48%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, CGEN is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check MIRM's competition here
CGEN vs SYRE Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, SYRE has a market cap of 5B. Regarding current trading prices, CGEN is priced at $2.02, while SYRE trades at $83.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas SYRE's P/E ratio is -39.42. In terms of profitability, CGEN's ROE is +0.48%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, CGEN is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check SYRE's competition here
CGEN vs TVTX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, TVTX has a market cap of 5B. Regarding current trading prices, CGEN is priced at $2.02, while TVTX trades at $53.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas TVTX's P/E ratio is -107.60. In terms of profitability, CGEN's ROE is +0.48%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, CGEN is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check TVTX's competition here
CGEN vs TERN Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, CGEN is priced at $2.02, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas TERN's P/E ratio is -51.41. In terms of profitability, CGEN's ROE is +0.48%, compared to TERN's ROE of -0.20%. Regarding short-term risk, CGEN is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check TERN's competition here
CGEN vs FOLD Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CGEN is priced at $2.02, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas FOLD's P/E ratio is -161.00. In terms of profitability, CGEN's ROE is +0.48%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, CGEN is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check FOLD's competition here
CGEN vs AKRO Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CGEN is priced at $2.02, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CGEN's ROE is +0.48%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, CGEN is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check AKRO's competition here
CGEN vs ERAS Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, ERAS has a market cap of 4.5B. Regarding current trading prices, CGEN is priced at $2.02, while ERAS trades at $14.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas ERAS's P/E ratio is -15.52. In terms of profitability, CGEN's ROE is +0.48%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, CGEN is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check ERAS's competition here
CGEN vs ALPN Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CGEN is priced at $2.02, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CGEN's ROE is +0.48%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CGEN is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check ALPN's competition here
CGEN vs CELC Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, CGEN is priced at $2.02, while CELC trades at $88.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas CELC's P/E ratio is -22.63. In terms of profitability, CGEN's ROE is +0.48%, compared to CELC's ROE of -2.45%. Regarding short-term risk, CGEN is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check CELC's competition here
CGEN vs OPT Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CGEN is priced at $2.02, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas OPT's P/E ratio is -1.52. In terms of profitability, CGEN's ROE is +0.48%, compared to OPT's ROE of +1.09%. Regarding short-term risk, CGEN is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check OPT's competition here
CGEN vs XENE Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, XENE has a market cap of 4.1B. Regarding current trading prices, CGEN is priced at $2.02, while XENE trades at $52.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas XENE's P/E ratio is -11.15. In terms of profitability, CGEN's ROE is +0.48%, compared to XENE's ROE of -0.49%. Regarding short-term risk, CGEN is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check XENE's competition here
CGEN vs MRTX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CGEN is priced at $2.02, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CGEN's ROE is +0.48%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CGEN is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check MRTX's competition here
CGEN vs TNGX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, TNGX has a market cap of 4.1B. Regarding current trading prices, CGEN is priced at $2.02, while TNGX trades at $32.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas TNGX's P/E ratio is -39.64. In terms of profitability, CGEN's ROE is +0.48%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, CGEN is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check TNGX's competition here
CGEN vs MANE Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, MANE has a market cap of 4B. Regarding current trading prices, CGEN is priced at $2.02, while MANE trades at $96.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas MANE's P/E ratio is -36.49. In terms of profitability, CGEN's ROE is +0.48%, compared to MANE's ROE of -0.95%. Regarding short-term risk, CGEN is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check MANE's competition here
CGEN vs KNSA Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, KNSA has a market cap of 3.9B. Regarding current trading prices, CGEN is priced at $2.02, while KNSA trades at $52.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas KNSA's P/E ratio is 57.52. In terms of profitability, CGEN's ROE is +0.48%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, CGEN is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check KNSA's competition here
CGEN vs VCYT Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, VCYT has a market cap of 3.9B. Regarding current trading prices, CGEN is priced at $2.02, while VCYT trades at $49.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas VCYT's P/E ratio is 45.51. In terms of profitability, CGEN's ROE is +0.48%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, CGEN is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check VCYT's competition here
CGEN vs CPRX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, CGEN is priced at $2.02, while CPRX trades at $31.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas CPRX's P/E ratio is 18.13. In terms of profitability, CGEN's ROE is +0.48%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, CGEN is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check CPRX's competition here
CGEN vs EWTX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, EWTX has a market cap of 3.8B. Regarding current trading prices, CGEN is priced at $2.02, while EWTX trades at $35.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas EWTX's P/E ratio is -21.21. In terms of profitability, CGEN's ROE is +0.48%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, CGEN is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check EWTX's competition here
CGEN vs RYZB Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CGEN is priced at $2.02, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CGEN's ROE is +0.48%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CGEN is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check RYZB's competition here
CGEN vs CBAY Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CGEN is priced at $2.02, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CGEN's ROE is +0.48%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CGEN is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check CBAY's competition here
CGEN vs CRNX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, CRNX has a market cap of 3.7B. Regarding current trading prices, CGEN is priced at $2.02, while CRNX trades at $35.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas CRNX's P/E ratio is -6.83. In terms of profitability, CGEN's ROE is +0.48%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, CGEN is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check CRNX's competition here
CGEN vs ACAD Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, CGEN is priced at $2.02, while ACAD trades at $21.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas ACAD's P/E ratio is 9.62. In terms of profitability, CGEN's ROE is +0.48%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, CGEN is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check ACAD's competition here
CGEN vs NAMS Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, NAMS has a market cap of 3.6B. Regarding current trading prices, CGEN is priced at $2.02, while NAMS trades at $30.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas NAMS's P/E ratio is -17.19. In terms of profitability, CGEN's ROE is +0.48%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, CGEN is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check NAMS's competition here
CGEN vs NAMSW Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, CGEN is priced at $2.02, while NAMSW trades at $18.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas NAMSW's P/E ratio is N/A. In terms of profitability, CGEN's ROE is +0.48%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, CGEN is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check NAMSW's competition here
CGEN vs SWTX Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CGEN is priced at $2.02, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas SWTX's P/E ratio is -13.78. In terms of profitability, CGEN's ROE is +0.48%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, CGEN is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CGEN.Check SWTX's competition here
CGEN vs DNLI Comparison June 2026
CGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGEN stands at 191M. In comparison, DNLI has a market cap of 3.5B. Regarding current trading prices, CGEN is priced at $2.02, while DNLI trades at $22.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGEN currently has a P/E ratio of 5.32, whereas DNLI's P/E ratio is -7.72. In terms of profitability, CGEN's ROE is +0.48%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, CGEN is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for CGEN.Check DNLI's competition here